tldrdaily.news logo

Viking Therapeutics' Weight-Loss Drug Fails to Impress Investors Amid High Dropout Rates

1 min read
Source: statnews.com
Viking Therapeutics' Weight-Loss Drug Fails to Impress Investors Amid High Dropout Rates
Photo: statnews.com
TL;DR Summary

Viking Therapeutics' oral weight loss drug VK2735 showed promising weight reduction in a Phase 2 trial, but high rates of gastrointestinal side effects and discontinuation have disappointed investors.

Topics:business#clinical-trial#health#side-effects#viking-therapeutics#vk2735#weight-loss-drug
Share this article
  1. Viking Therapeutics oral weight loss drug hits mark in mid-stage trial but disappoints investors  statnews.com
  2. Viking Therapeutics stock crashes after weight-loss pill trial shows high dropout rate  Yahoo Finance
  3. Viking Therapeutics shares fall 40% on disappointing obesity pill trial data  CNBC
  4. High drop-out rate clouds weight loss data for Viking's oral drug  FirstWord Pharma
  5. This Weight-Loss Stock Is Down 40%. It Lowers the Risks for Eli Lilly and Novo Nordisk.  Barron's

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

1 min

vs 2 min read

Condensed

87%

223 → 28 words

Want the full story? Read the original article

Read on statnews.com